

IFW

Attorney Docket No.: 112911.00151

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :
Shi :
Serial No. 10/769,218 : Group Art Unit: Not yet assigned
Filed: January 30, 2004 : Examiner: Not Yet Assigned

For: CASPACE-9:BIR-DOMAIN OF XIAP COMPLEXES AND METHODS
OF USE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Mail Stop DD
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. Copies are provided. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to deposit account no. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

A handwritten signature in black ink, reading "Raymond A. Miller". The signature is fluid and cursive, with the first name "Raymond" being more prominent than the last name "Miller".

Raymond A. Miller
Registration No. 42,981

Pepper Hamilton LLP
One Mellon Bank Center
50th Floor
500 Grant Street
Pittsburgh, PA 15219
Telephone: (412) 454-5813
Facsimile: (412) 281-0717
Date: August 6, 2004



CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

APPLICANT: Shi

TITLE: CASPACE-9:BIR-DOMAIN OF XIAP COMPLEXES AND METHODS OF USE

SERIAL NO. 10/769,218

ATTORNEY REF: 112911.00151

DATE OF DEPOSIT: August 6, 2004


I HEREBY CERTIFY THAT THIS INFORMATION DISCLOSURE STATEMENT WITH COPIES OF REFERENCES CITED THEREIN IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE VIA FIRST CLASS MAIL UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO COMMISSIONER FOR PATENTS, MAIL STOP AMENDMENT, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Jennifer Martinez

(Typed or printed name of person mailing paper or fee)

Documents Enclosed:

1. Information Disclosure Statement with cited references;
2. Certificate of Mailing;
3. Postcard



Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number	10/769,218		
				Filing Date	January 30, 2004		
				First Named Inventor	Shi		
				Group Art Unit	Not yet assigned		
				Examiner Name	Not yet assigned		
Sheet	1	of 2		Attorney Docket Number	112911.00151		
U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code (if known)				
	AA	6,187,557	B1	Rothe et al.	02-13-2001		
	AB	6,110,691	B1	Wang et al.	8/29/2000		
	AC	09/965,967	A	Princeton University			
	AD	20020132786	A2	Alnemri	9/19/2002		
	AE	20020160975	A2	Alnemri	10-31-2002		
	AF	20040054148	A2	Alnemri	3-18-2004		
FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number				
	BA		WO 99/15657		Curagen Corporation	04-01-1999	
	BB		WO02/16418	A1	Thomas Jefferson University	28-02-2002	
	BC		WO02/26775	A2	The Trustees of Princeton University	04-04-2002	
	BD		WO02/30959	A2	Abbot Laboratories	04-18-2002	
	BE		WO02/96930	A2	The Trustees of Princeton University	12-05-2002	
	BF		WO03/018014	A2	The Government of the United States of America	03-06-2003	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.					
	CA	DEVERAUX, ET AL., <i>IAP family proteins-suppressors of apoptosis</i> ; Genes Dev. 13: 239-252, 1999.					
	CB	KASOF, ET AL.; <i>Livn, a novel inhibitor of apoptosis protein family member</i> ; J Biol. Chem. 276: 3238-3246, 2001.					

CC	VUCIC DOMAGOJ, ET AL.; <i>ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas</i> ; Curr. Biol. 10:1359-1366, 2000.
CD	ASHAB, YAQOUB, et al. <i>Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution</i> ; Federation of European Biochemical Societies Letters 495:56-60, 2001.
CE	DU, CHUNYING, ET AL.; <i>Smac, a Mitochondrial protein that promotes cytochrome c-dependent Caspase activation by eliminating IAP inhibition</i> ; Cell 102:33-42, 2000.
CF	VERHAGEN, ET AL.; <i>Identification of DIABLO, a mammalian protein that promotes Apoptosis by binding to and antagonizing IAP proteins</i> ; Cell 102:43-53, July 7, 2000.
CG	HAY, B.A.; <i>Understanding IAP function and regulation: a view from Drosophila</i> ; Cell Death Differ. 7:1045-1056, 2000 (Abstract).
CH	BOXRUD, PAUL., D., ET AL.; <i>Streptokinase binds to human plasmin with high affinity, perturbs the plasmin active site, and induces expression of a substrate recognition exosite for plasminogen</i> ; J. Biol. Chem. 275: 14579-14589, 2000.
CI	OWENIUS, RIKARD, ET AL.; <i>Properties of spin and fluorescent labels at a receptor-ligand interface</i> , Biophys. J. 77:2237-2250, 1999.
CJ	HIRATSUKA, TOSHIAKI, <i>ATP-induced opposite changes in the local environments around CYS⁶⁹⁷(SH2) and Cys⁷⁰⁷(SH1) of the myosin motor domain revealed by the prodan fluorescence</i> , J. Biol. Chem. 274:29156-29163, 1999.
CK	CHAN, W.C., White, P.D., <i>Fmoc Solid Phase Peptide Synthesis: A Practical Approach</i> ; Oxford University Press: Oxford 2000 (Table of Contents).
CL	FREIDINGER, ROGER, M., ET AL.; <i>Synthesis of 9-fluorenylmethyloxycarbonyl-protected n-alkyl amino acids by reductive oxazolidinones</i> , J. Org. Chem. 48:77-81, 1983.
CM	SRINIVASA, et al.; <i>A conserved XIAP-interaction motif in Caspase-9 and Smac/DIABLO regulates Caspase activity and apoptosis</i> ; Nature, Vol 410 pp. 112-116; March 2001
CN	TERWILLIGER, ET AL.; <i>Correlated Phasing of Multiple Isomorphous Replacement Data</i> ; Acta Cryst. (1996) D52, 749-757
CO	BAILEY, ET AL.; <i>The CCP4 Suite: Programs for protein crystallography</i> ; Acta Cryst. (1994) D50, 760-763
CP	SUN, ET AL.; <i>NMR Structure and Mutagenesis of the Third Bir Domain of the Inhibitor of Apoptosis Protein XIAP</i> ; J of Biol. Chem; Vol. 275, Issue of October 27, pp. 33777-33781, 2000
CQ	RIPKA, et al.; <i>PEPTIDOMIMETIC DESIGN</i> ; Chem. Biol. 1998, 2:441-452, 1998
CR	NICHOLLS, et al.; <i>Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons</i> ; Proteins: Structures, Functions and Genetics 11:281-296 (1991)
CS	NAVAZA, J.; <i>AmoRE: an automated package for molecular replacement</i> ; Acta Cryst. (1994) A50, 157-163
CT	MORGAN, ET AL.; Ch. 26, Section VI-Topics in Chemistry and Drug Design, "Approaches to the Discovery of Non-Peptide Receptors and Peptidases"; Academic Press, Inc., 1989
CU	McCARTHY, ET AL.; <i>Apoptosis induced by Drosophila Reaper and Grim in a Human System</i> ; J. Biol. Chem.; Vol. 273, No. 37, September 11, 1998; pp. 24009-24015
CV	LIU, ET AL.; <i>Structural basis for the binding of SMAC/DIABLO to the XIAP BIR3 Domain</i> ; Nature Vol.408 21/28 December 2000, pp. 1004-1008
CW	LISI, ET AL.; <i>Diverse domains of THREAD/DIAP1 are required to inhibit apoptosis induced by REAPER and HID in drosophila</i> ; Genetics 154:669-678; February 2000
CX	KRAULIS, J.; <i>Molscript: a program to produce both detailed and schematic plots of protein structures</i> ; J. Appl. Cryst. (1991) 24, 946-950
CY	JONES, ET AL.; <i>Improved methods for building protein models in electron density maps and the location of errors in these models</i> ; Acta. Cryst.(1991) A47,110-119
CZ	HRUBY, ET AL.; <i>Synthesis of oligopeptide and peptidomimetic libraries</i> ; J. Chem. Biol. 1997; 1:114-119; http://biomednet.com/elecref/1367583199199114
CCA	HRUBY, ET AL.; <i>Conformational and topographical considerations in designing agonist Peptidomimetics from peptide leads</i> ; Current Med. Chemistry, 2000, 7, 945-970
CCB	GOYAL, ET AL.; <i>Induction of Apoptosis by Drosophila Reaper, hid and grim through inhibition of IAP function</i> ; EMBO Journal, Vol. 19, No. 4, pp. 589-587, 2000
CCC	DU, ET AL.; <i>SMAC, a mitochondrial protein that promotes cytochrome c-Dependent Caspase activation by eliminating IAP inhibition</i> ; Cell, Vol. 102, 33-42, July 7, 2000
CCD	CHEN, PO., ET AL.; <i>Grim, a novel cell death gene in Drosophila</i> ; Genes & Development 10:1773-1782 (1996)
CCE	AMBROSINI, GRAZIA, ET AL.; <i>Induction of Apoptosis and Inhibition of Cell Proliferation by surviving gene targeting</i> ; J of Biological Chemistry; Vol. 273, No. 18, May 1, 1988; pp. 11177-11182
CCF	VUCIC, DOMAGOJ, ET AL.; <i>Inhibition of Reaper-induced apoptosis by interaction with inhibitor of apoptosis proteins (IAP)</i> ; Proc. Natl. Acad. Sci, USA, Vol. 94, pp. 10188, September 1997
CCG	CHAI, JIJIE, ET AL.; <i>Structural and Biochemical basis of apoptotic activation by Smac/DIABLO</i> ; Nature; Vol. 406, pp. 855862, August 2000
CCH	SRINIVASA, M. SRINIVASULA, ET AL.; <i>Molecular Determinants of the Caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway</i> ; J.Biological Chem., V. 275, No. 46, Nov. 17, 2000, pp. 36152-36157

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.